

Register before
30 September and
save USD 500!

Booking form on
back page

Gold Sponsor



Silver Sponsor



Associate Sponsor

China's **No. 1** *Biopharmaceutical conference of the year!*

Bio

World China

世界生物制药—中国

29 Nov to 1 Dec 2011, Shanghai, China

Biopharma CEOs



Su Chen,
Chengdu Kanghong
Pharmaceutical Group, China



Scott Liu,
Henlius Biopharmaceutical
Inc, USA



Yan Feng Ying,
Tianjin Hualida Biotechnology,
China



Li Shi,
Shanghai ZerunBiotechnology,
China



Li Huicheng,
Harbin Pharmaceutical Group
Bioengineering, China

Biomanufacturing Leaders



Christian Leist, Head of BioProcess
Development & Technology
Platform Manager, Novartis Pharma
AG, Switzerland



Joe Zhou,
CEO, Genor
Biopharmaceuticals, China



Karen Wen,
Founder and President,
Mycenax Biotech, Taiwan



Feng Li,
CEO,
Beijing Mab-Works Inc, China



M.S Mahadevan,
Director, Strategic Marketing,
Process Solutions Business Unit
Merck Millipore, India

Biotherapeutic R & D Leaders



Grace Wong, CEO, Actokine
Therapeutics, USA



Zhenping Zhu, EVP, Global
Biologics R&D, President &
CEO, Kadmon China



Allan Liu, VP, WangBang
Biopharma, China



Yining Zhao, Senior Director, Asia
Strategy, Pfizer, USA



Dr. Baoping Wang
President Nordisk Pharmaceuticals,
China

Supporting Partners



Proudly created and produced by

IMAPAC
Imagine Your Impact

Letter from the Chairman

Dear friends and colleagues,

Welcome to Bio World China 2011. The Organizing Team at IMAPAC has gathered 50 top speakers in our industry and presented this golden opportunity to share new ideas and discuss current trends in the fast changing biopharmaceutical landscape. Being a part of this noble industry equips each of us with the ability to change the lives of many millions of people we may never meet. Our contributions can come in many forms, from the laboratory researches, to plant and process designs, to the operational and execution of manufacturing facilities and quality assurance. However, there is a common goal to be achieved, and that is to be able to relieve the pain and suffering caused by disease.

With the rising cost of living globally, there is a need to ensure that healthcare remains affordable and accessible to all. No one should be denied the access to effective and affordable medicine. Hence to achieve that goal, we must transform good research into effective products that can be reproduced in large quantities and meet all regulatory and quality standards. It is always a challenge to efficiently scale-up both upstream and downstream bioprocesses, and the industry relies heavily on the constant advancements in technological solutions, some of which we will learn from at this conference.

China's biopharmaceutical landscape is changing rapidly. Several new Chinese biotechs have sprouted and are leading novel discoveries in the Asia-pacific targeted disease areas. They are headed by returning Chinese or what people call "sea turtles", many of which used to work for big multinationals. The constant revision of GMP standards and strong funding from the government is a sign of the huge potential of the Chinese market. However to go beyond the domestic market, it is necessary for Chinese manufacturers to bring IP, manufacturing technologies, regulatory standards, marketing approaches and information barriers in line with the global best practices.

Bio World China 2011 is the definitive venue for receiving first-hand information on the current international status of the Biopharmaceutical industry and China's biopharmaceutical opportunities. It will bring you the latest developments in products, process technologies, IP, quality, and regulatory developments. Come to the meeting to establish and renew partnerships to help develop new products, acquire new process technologies, and establish new contract manufacturing relationships.

I am looking forward to meeting each and every one of you, will be speaking about my own experiences, and look forward to hear about yours. I encourage you to join us and share the excitement of new ideas and endless possibilities.

Come join me in Shanghai at Bio World China this November. Let us talk, and listen together so we can share our knowledge, stimulate the growth of our industry and better help improve the lives of people worldwide.

Sincerely,

Steven Lee
CEO, A-Bio, Singapore

ADVISORY BOARD

At IMAPAC, we don't teach fish how to swim, we asked the big fish to do it for us. We are honoured that our programme is being created with the knowledge support of the industry's top minds. And they are:



Don Gerson



Christian Leist




Joe Zhou



Steven Lee



Grace Wong



Uwe Gottschalk

EVENT AT A GLANCE



DAY 1: 29 NOV TUESDAY

DAY 2: 30 NOV WEDNESDAY

DAY 3: 1 DEC THURSDAY

<p>Bio CEO Conclave 中国生物制药CEO论坛</p> <p><i>BioCEO Conclave is an exclusive closed-door CEO discussion and networking forum, featuring China's most aspiring biopharma leaders.</i></p> <p>Close door round table discussion</p> <p>Break</p> <p>Closed door round table discussion</p> <p>Welcome Cocktail</p>	<p>Bio Therapeutics World 世界生物药研发峰会</p>		<p>Bio Manufacturing World 世界生物药生产峰会</p>		<p>Cell Culture Engineering World 世界细胞培养工程技术论坛</p>		<p>Bio Manufacturing World 世界生物药生产峰会</p>	
	<p>Joint Plenary: The future of Biologics in the new GMP regulated China</p>				<p>Cell Culture in the era of Biologics</p>		<p>Downstream Processing Economy & new advancement</p>	
	<p>Morning Refreshments</p>				<p>Morning Refreshments</p>			
	<p>Biosimilars and biobetters development</p>		<p>Big Pharma's Biomanufacturing strategy, regulation, relocation & networks</p>		<p>Cell Line Engineering & Selection</p>		<p>OhD & PAT</p>	
	<p>Networking Lunch & Exhibition Visit</p>				<p>Luncheon</p>			
	<p>Bio-equivalence & characterization</p>		<p>Single-use and Disposable Technology</p>		<p>Media Selection and Optimization</p>		<p>Design and operational excellence</p>	
	<p>Afternoon Refreshments & Exhibition Visit</p>				<p>Afternoon Refreshments & Exhibition Visit</p>			
	<p>Biotherapeutics and Therapeutics Vaccines developments</p>		<p>Process Development and Scale-up Best Practices</p>		<p>New & next generation cell culture expression systems & facilities</p>		<p>Design and operational excellence</p>	
	<p>Dinner & Social Activities</p>				<p>Closing Plenary: Glimpse into the future</p>			
	<p>Exhibition & Showcases</p>							

Bio CEO Conclave

中国生物制药CEO论坛

BioCEO Conclave

is an exclusive closed-door CEO discussion and networking forum, featuring China's most aspiring biopharma leaders. Join them to gain first-hand information on how China's future biopharma industry will be shaped and hear their personal insights and opinion of the rapidly changing biopharma landscape.

Here are just some of the leading Chinese biopharma leaders whom you can expect to meet...

- CEO, Genor Biopharma
- CEO, Chengdu Kanghong Pharmaceutical
- CEO, Shanghai Zerun Biotechnology
- CEO, Harbin Pharmaceutical Group
- CEO, Harbin Pharmaceutical Engineering
- CEO and President, Shenzhen Neptunus Interlong Bio-tech
- President, Beijing Four Rings Biopharmaceutical etc.
- CEO, Guangdong Techpool BioPharma
- CEO, Tianjin Hualida Biotechnology
- CEO, Shenzhen SiBiono GeneTech
- CEO, Zhuhai Essex Bio-Pharmaceutical
- CEO, NCPC GeneTech Biotechnology development Co. Ltd
- CEO, Chengdu Hoist Biotechnology
- CEO, Innovent Biologics, Inc.
- CEO, Jiangxi Boya Bio pharmaceutical
- CEO, Biosino Bio-Technology & Science Inc.

If you are a President or CEO from a Chinese biopharmaceutical organization, please write to us at jasmine.wong@imapac.com to know more about how you can be part of it. If you want to be an observer for the CEO conclave, register today as seats are limited to 20!

Your Opportunity to Capture China's Rapidly Growing Biopharmaceutical Market

BioWorld China 2011 will give you the unique opportunity to position your business in front of decision makers of the Chinese and global biologics and vaccines manufacturers. In order to get the right audience for you, our internal resources are fully geared towards attracting the largest and leading companies in the biopharmaceutical space in China and the rest of the world. We also work with a wide range of media partners and industry bodies to guarantee this audience.

Why should you sponsor?

Bio World China 2011 will provide commercial organisations with the opportunity to:

- Educate the market about what you offer
- Raise brand awareness and position yourselves as leaders in your field
- Maximize your face time with key profiles from biopharma R&D, cell culture and biomanufacturing, all in a single location
- Enjoy the option of privately arranged meetings and consultations with selected potential clients
- Hold face to face meetings with your target profile

Who should sponsor?

World-class solution providers who need to position their products and services in front of decision makers from major biologic and vaccine manufacturers

- | | |
|--|--------------------------------|
| • Contract Manufacturing Organisations | •Distribution and Logistics |
| •Contract Research Organisations | •Cold Chain Storage |
| •Equipment Providers | •Packaging |
| •Biologics Technology Platforms | •Regional Development Agencies |
| •Bioprocess Technology Platforms | •Biotechs |
| •Consultants in process and plant design | |

No other Biopharmaceutical event can get you more face time with decision makers from all profiles including R&D, cell culture development and biomanufacturing from China and global leaders. Make sure you get access to China's booming biopharmaceutical industry and aren't missing out this opportunity. See a real ROI by being a part of the industry's most comprehensive marketing campaign. Seize this exceptional opportunity to position your brand and business before China and global biopharma business leaders at Bio World China 2011.



To find out more about becoming one of our partners for this event, please do not hesitate to contact Jasmine Wong +65 6493 1598 or e-mail jasmine.wong@imapac.com

JOINT PLENARY :



- 8.55 IMAPAC welcome remarks
- 9.00 Shanghai government official Guest-of-Honor welcome speech
- 9.05 Chairman's opening remarks
Steven Lee, Global Head, Biologics Business at Luye Pharmacy Group, CEO, A Bio, Singapore (confirmed)

BIOLOGIC INDUSTRY OUTLOOK IN CHINA

- 9.10 In conversation with Biopharma leaders: The future of Biologics in the new GMP regulated China
- Moving from biosimilars to innovation model: promises and challenges and timing
 - What biosimilar, biobetter or new biotherapeutics to develop: redefine your priority
 - Evaluate risks when developing biosimilars versus new products
- PANELISTS**
Scott Liu, CEO, Henlius biopharmaceutical, USA (confirmed)
Li Shi, CEO, Zerun Biotechnology, China (confirmed)
Su Chen, CEO, Chengdu Kang Hong, China (confirmed)

- 9.55 **Biotherapeutic Leadership Panel: Uncovering the hidden treasure of China's biotherapeutic R&D**
- Is there innovative biotherapeutic development in China? Who are they?
 - What role does big pharma, China pharma, biotech and academics play in the innovation landscape
 - From made-in-china to innovate-in-China: a myth or reality?

MODERATOR

Kelvin Shao, Director, Business Development, New Summit BioPharma, China (confirmed)

PANELISTS

Dr. Baoping Wang, Vice President of Novo Nordisk R&D, and Head of Beijing Novo Nordisk pharmaceuticals Co. Ltd, Novo Nordisk, China (confirmed)

Yining Zhao, Senior Director, Asia Strategy, Pfizer, USA (confirmed)

Zhenping Zhu, Executive Vice President, Global Biologics R&D, President & CEO, Kadmon China (confirmed)

- 10.40 Morning refreshment and speed networking



BIG PHARMAS' BIOMANUFACTURING STRATEGIES, REGULATION, RELOCATION AND NETWORKS

- 11.30 **Keynote: China as the strategic location for Multinational Pharma's global biomanufacturing operations: why, where and how?**
- Why manufacture biologics China and what to manufacture?
 - Top 3 criteria to consider when choosing the right manufacturing location
 - Buy out an existing facility or build your own?
 - What role does China plays in the global biomanufacturing network?
- Cleo Ricci, Vice President Manufacturing Operation at UCB, Belgium (invited)**

- 12.00 **Regulation, Validation and Compliance of your manufacturing facility**
- Understanding the changing regulatory landscape in China from the perspective of the regulators and the industry
 - Dissecting the challenges faced by the industry in validation and compliance
- Joe Zhou, CEO, Genor BioPharma, China (confirmed)**

- 12.45 **Networking Luncheon**

SINGLE-USE AND DISPOSABLE TECHNOLOGY

- 14.00 **Enclosure analysis when designing a GMP plant made up of 100% single-use technology**
Bo Xu, Senior Director of Bioprocess and BioManufacturing, WuXi Apptec, China (confirmed)
- 14.30 **Case study: Scale and economic comparison between single-use and stainless steel**
Karen Wen, Founder and President, Mycenax Biotech, Taiwan (confirmed)
- 15.00 **Buyers and Sellers Dialogue: Why single-use and why not?**
- The case for and against implementing single use technology in biopharmaceutical manufacturing
 - Economic considerations in single use technology
- CHAIR**
Christian Leist, Lead scientist and Head bioprocess, Novartis, Switzerland (confirmed)
- PANELISTS**
Karen Wen, Founder and President, Mycenax Biotech, Taiwan (confirmed)
Bo Xu, Senior Director of Bioprocess and BioManufacturing, WuXi Apptec, China (confirmed)
Fei Jiang, Head of R&D, 3S Bio, China (confirmed)

- 15.30 **Afternoon tea and refreshment & Exhibition Visit**

PROCESS DEVELOPMENT AND SCALE-UP BEST PRACTICES

- 16.00 **Addressing scale-up challenges in vaccine manufacturing**
- Unique challenges for scale up in vaccines manufacturing
 - Process optimization and challenges anticipated for commercial scale manufacturing.
- Don Gerson, CEO, Pnuvax, Canada (confirmed)**
- 16.30 **Roundtable small group discussion:**

This roundtable discussion session is an open moderated session where delegates are divided into two groups to discuss a set of topics. Moderated by key industry experts, the roundtable discussion will ensure debates and discussions on thought-provoking and controversial issues with industry peers.

Roundtable 1: How to bridge upstream and downstream yield and expectations

Roundtable 2: Best practices to address protein folding and glycosylation challenges during scale-up

- 17.30 Chairman closing remarks

Cocktail and post event activities

JOINT PLENARY :



- 8.55 IMAPAC welcome remarks
- 9.00 Shanghai government official Guest-of-Honor welcome speech
- 9.05 Chairman's opening remarks
Steven Lee, Global Head, Biologics Business at Luye Pharmacy Group, CEO, A Bio, Singapore (confirmed)

BIOLOGIC INDUSTRY OUTLOOK IN CHINA

- 9.10 In conversation with Biopharma leaders: The future of Biologics in the new GMP regulated China

- Moving from biosimilars to innovation model: promises and challenges and timing
- What biosimilar, biobetter or new biotherapeutics to develop: redefine your priority
- Evaluate risks when developing biosimilars versus new products

PANELISTS

Scott Liu, CEO, Henlius biopharmaceutical, USA (confirmed)

Li Shi, CEO, Zerun Biotechnology, China (confirmed)

Su Chen, CEO, Chengdu Kang Hong, China (confirmed)

- 9.55 Biotherapeutic Leadership Panel: Uncovering the hidden treasure of China's biotherapeutic R&D

- Is there innovative biotherapeutic development in China? Who are they?
- What role does big pharma, China pharma, biotechs and academics play in the innovation landscape
- From made-in-china to innovate-in-China: a myth or reality?

MODERATOR

Kelvin Shao, Director, Business Development, New Summit BioPharma, China (confirmed)

PANELISTS

Dr. Baoping Wang, Vice President of Novo Nordisk R&D, and Head of Beijing Novo Nordisk pharmaceuticals Co. Ltd, Novo Nordisk, China (confirmed)

Yining Zhao, Senior Director, Asia Strategy, Pfizer, USA (confirmed)

Zhenping Zhu, Executive Vice President, Global Biologics R&D, President & CEO, Kadmon China (confirmed)



BIOSIMILARS AND BIOBETTERS DEVELOPMENT

- 11.30 Fortress Besieged: MNC's and Local Biopharma's Different Perspectives on Partnering to Capture China's Biosimilar/ Biologics Opportunities
- Can biotherapeutics sales growth trend continue on a larger scale?
 - Which domestic players are leaders today and can be partners for the future?
 - What are MNCs considering when evaluating the biosimilar market in China and what are their entry strategies going forward?
- Yining Zhao, Senior Director, Asia Strategy, Pfizer, USA (confirmed)

- 11.55 Developing biobetters for differentiation
- Evaluating market worth of biobetters by examining the potential payoff.
 - Marketing challenges for biobetter drugs
 - Regulatory challenges in development of biobetters
- Michael Yu, CEO, Innovent Biologics, China (confirmed)

- 12.25 Identify new biologics for radioprotection and radioprotective biomarkers for new drug screening
- Grace Wong, CEO, ActoKine Therapeutics, USA (confirmed)

- 12.45 Networking Luncheon

FORMULATIONS AND CHARACTERIZATION

- 14.00 Case studies on characterization of protein in R&D, Clinical and Manufacturing stages

- Characters of big molecules and its method of characterization
- Stability and structure analysis
- Technology transfer and quality assurance

George Wang, Senior Director, Analytical Sciences, Formulation & Quality, Genor Biopharma, China (confirmed)

- 14.30 Strategic use of innovative analytical technologies to improve drug quality and bioprocess productivity

- Obtaining the data for mechanisms of protein stability and instability generated from the analysis
- Maximizing the use of the data generated for feasibility studies

- 15.00 Formulation strategies that improves protein stability

- Strategies that reduce degradation in solution
- Strategies by using lyophilized formulations and their advantages
- Case studies

Nazaneen Pourkavoos, Principal Scientist protein formulation and drug delivery, Novo Nordisk A/S, Denmark (invited)

- 15.30 Afternoon tea and refreshment & Exhibition Visit

CASE STUDIES: BIOTHERAPEUTICS AND THERAPEUTIC VACCINES DEVELOPMENTS

- 16.00 Case study: Best practices in biotherapeutic research and development

Zhenping Zhu, Executive Vice President, Global Biologics R&D, President & CEO, Kadmon China (confirmed)

- 16.20 In Vitro-Activated Cancer Vaccines: A Revolution Model of Medical Treatment and Business

- The case study of Provenge as a cancer vaccine
- Challenges of individual medicine versus personalized medicine development
- A comparison of business models of traditional pharma versus personalized medicine

Allan Liu, VP, WangBang Biopharma, China (confirmed)

- 16.40 Case study: Novel antibody target for cancer

Jian Ni, CEO and Chief Scientist, Human Antibodomics Inc, China (confirmed)

- 17.00 Case study: Bat-2094: A novel monoclonal antibody for cardiovascular diseases

Shengfeng Li, CEO, Sinoasis Pharmaceuticals, China (confirmed)

- 17.20 Case study: Anti-CD133 anti-CD3 bi-specific antibody biobetter

Pengfei Zhou, Chief Scientific Officer Wuhan YZY Biopharma Co., Ltd, China (confirmed)

- 17.40 Chairman closing remarks

Cocktail and post event activities



9.00 Imapac welcome remarks

9.05 Chairman's welcome

DOWNSTREAM PROCESSING ECONOMY AND NEW ADVANCEMENT

9.10 **Keynote: Leveraging innovation to transform bioprocess productivity: Bridging the gap between upstream productivity and downstream process**

Sunil Gupta, Vice President and Head, Global Biological Development, Bayer Healthcare, USA (confirmed)

9.40 **Modern Cost-Effective Solutions for the Capture and Purification of Biosimilars**

- Advances in biotechnologies for biosimilars
- Affinity ligands for suitable selective capture
- Development and application of synthetic-ligand affinity capture adsorbents for biosimilars

Steve Burton CEO, Prometic Bioscience Ltd (confirmed)

10.10 **Downstream processing innovation: Promising technologies on the horizon**

- Alternatives to protein A
- Single-use downstream chromatography
- New affinity purification methods

Fei Jiang, Head of R&D, 3S Bio, China (confirmed)

10.40 **Morning refreshments and exhibition visit**

QbD and PAT

11.10 **The importance of implementing "built-in quality concept" for global biomanufacturing expansion and success**

- Platform Process with built-in QbD concept
- Platform Process Robustness to be fit for Phase III
- PAT for Process Control
- Down Scale Modeling for facilitation and Acceleration Process Characterization

Christian Leist, Novartis Leading Scientist, Head of Bioprocess development group, Novartis, Switzerland (confirmed)

11.40 **PAT and QbD implementation concepts to support Knowledge Management in Bioprocess**

- Impact of QbD implementation to information and knowledge management concepts
- Novel aspects to DoE studies
- Feedback of the FDA QbD pilot program
- Case studies of successful process control automation technology applications

12.10 **The use of Design of Experiments (DoE) to optimize bioprocess systems and to add value to the biomanufacturing value chain**

- The application of DoE along the full bioprocess value chain
- Successful case studies of recombinant protein expression optimization

Andree Ellert, Product Manager, Sartorius Stedium Biotech, Germany (confirmed)

12.40 **Networking Luncheon**

DESIGN AND OPERATIONAL EXCELLENCE

14.00 **Built for the future - designing a sustainable bio-pharmaceutical facility**

- The challenges of achieving LEED and sustainable design in the biopharma industry
- The implications of not opting for sustainable design
- Case study of a successful LEED project

Pierre Trotemann, Head of Industrial Operations, Sanofi Pasteur, China (invited)

14.30 **Addressing Challenges in cold chain management and the distribution of biopharmaceuticals to ensure post-manufacturing quality**

- Challenges in developing and implementing internationally recognized standards for cold chain in China
- Aligning developments to suit second and third tier cities in China

Michael Lee, VP Manufacturing, Biomabs, China (confirmed)

15.00 **Case study: Deciding to go green and what you need to do**

- Looking beyond the low hanging fruit to save water and energy
- Incentives and education to gain buy-in across organization
- Using quantifiable results to justify and reap benefits of green initiatives

Jizhong Shan, Senior Director, Genzyme Beijing Operations, China (Invited)

15.30 **Afternoon refreshment & Exhibition Visit**

16.00 **Case study: Deciding to outsource or In-house manufacturing in China**

- The need to have localized manufacturing to meet market demand
- Factors to consider to outsource or do it in-house
- Selection Criteria when choosing location and partners

Charles Shank, Senior Director, Merck & Co., Inc., China (Invited)

16.30 **Closing plenary: Wrapping up and taking a glimpse into the future**

- Key lessons learnt for biomanufacturing in China and implementation strategies
- Crystal-balling future trends for biologic drugs development globally and in China
- The road ahead for biopharmaceutical manufacturers in China and the ingredients for long term success

MODERATOR

William Keller, General Manager, Zhangjiang High-Tech Park, Shanghai, China (Invited)

PANELISTS:

Kelvin Shao, Director, Business development, New summit biopharma, China (confirmed)

Steven Lee, CEO, ABio, Singapore (confirmed)

Charles Shank, Senior Director, Merck & Co., Inc., China (Invited)

Roberto Silveria, VP, Biomanufacturing Sciences, Pfizer, USA (Invited)

17.30 **Chairman's closing remarks**



世界细胞培养工程技术论坛

<p>9.00 Welcome Remarks</p> <p>9.05 Chairman's Welcome</p> <p style="text-align: center;">CELL CULTURE IN THE ERA OF BIOLOGICS</p> <p>9.10 Keynote: The evolving cell-culture based biomanufacturing: Promises and challenges</p> <ul style="list-style-type: none"> • Innovative strategies and new technologies available for improved performance • What are the critical challenges to be considered when using cell culture systems for biomanufacturing? • Where do future developments need to be made to improve cell culture-based bioproduction <p>Herve Broly, Vice President Biotech Process Development, Merck Serono, Switzerland (confirmed)</p> <p>9.40 Industrialization of vaccine production: Impact of cell culture process development</p> <ul style="list-style-type: none"> • The evolution of manufacturing process for vaccine • What is the focus of cell culture process development efforts shifting towards? • Possible implications for product development strategies <p>Lin WeiLii, President , Vaccine Medigen Biotechnology Corp, Taiwan (invited)</p> <p>10.10 Standardize first optimize later: Strategy for clone and culture optimization</p> <ul style="list-style-type: none"> • Creating a strong standard culture media the pros and cons • Platform media and its use in clone selection • Media optimization post clone selection <p>Feng Li, CEO, Beijing Mab-Works, Inc, China (confirmed)</p> <p>10.40 Morning refreshments and exhibition visit</p> <p style="text-align: center;">CELL LINE ENGINEERING AND SELECTION</p> <p>11.10 CHO cell engineering – Current available tools and technologies for improved yield</p> <ul style="list-style-type: none"> • microRNAs: New Tools to Manipulate Protein Expression in CHO Cells • genome wide expression profiling to identify potent endogenous promoters • auditioning CHO via artificial chromosome expression (ACE) technology <p>Chi Wei-Kuang, Vice President, Development Center for Biotechnology, Taiwan (invited)</p> <p>11.40 Next generation technology for production of biopharmaceuticals in human amniocytes</p> <ul style="list-style-type: none"> • Obtaining high production yields of recombinant proteins by using novel technology • Understanding advantages of the new technology: allowing for high yield production of recombinant proteins, with excellent biologic activity and therapeutic activity as a result of post-translational modification. • Development of the new technology as a unique platform from early pre-clinical evaluation up to clinical supply <p>12.30 Panel discussion: Evaluating optimal technologies and techniques for cell line engineering</p> <ul style="list-style-type: none"> • What technologies are required to improve cell line engineering? • Evaluating mammalian cells as hosts for the production of recombinant proteins, vaccines and cell therapy • New developments: improving how cells grow in culture; using platform technologies to improve host capabilities; developing cell line stability and maintaining secretion levels <p>Moderator: Steven Lee, CEO, A Bio, Singapore (confirmed)</p> <p>Panelists:</p> <p>Herve Broly, Vice President Biotech Process Development, Merck Serono (confirmed)</p> <p>Feng Li, CEO, Beijing Mab-Works, Inc, China(confirmed)</p> <p>Chi Wei-Kuang, Vice President, Development Center for Biotechnology, Taiwan (invited)</p>	<p>12.50 Networking Luncheon</p> <p style="text-align: center;">MEDIA SELECTION AND OPTIMIZATION</p> <p>14.00 Media development challenges and opportunities for high throughput media development</p> <ul style="list-style-type: none"> • Key considerations for media and feed development: safety, quality and robustness • Media formulation strategies for high throughput media development • Novel assay methods and high throughput tools for optimization of cell culture parameters <p>14.30 Maximizing CHO cell productivity via customer media development</p> <ul style="list-style-type: none"> • Optimising the performance of a cell culture-based manufacturing systems via the selection of optimal media supplements • Comparing synthetic media supplements with animal-derived supplements: advantages and disadvantages given the application of cultured cells • Considering chemically-defined media: advantages and disadvantages and current industry usage <p>15.00 Optimizing cell culture procedures upstream</p> <ul style="list-style-type: none"> • Strategies for generating cell culture processes with high titre, robustness and improved scale-up efficacy potential • Defining a media formulation to maximise protein production and significantly improve product titres, thereby reducing costs and improving efficacy • Examining the advantages and specific requirements of developing a robust serum-free cell culture media containing defined animal-free protein supplements <p>15.30 Afternoon refreshment & Exhibition Visit</p> <p style="text-align: center;">NEW AND NEXT GENERATION EXPRESSION SYSTEMS AND CELL CULTURE FACILITIES</p> <p>16.00 Engineering molecular chaperones for improved specific foreign protein productivity in recombinant CHO cells</p> <p>Gyun-Min Lee, Professor, KAIST, Korea (invited)</p> <p>16.30 Utilizing genome wide expression profiling to identify potent endogenous promoters for CHO based manufacturing of therapeutic proteins</p> <p>Scott Estes, Director, BioPharma Development, Biogen Idec, USA (invited)</p> <p>17.00 Case study: Micro carrier-based MDCK cell culture system for the production of influenza H5N1 vaccines</p> <ul style="list-style-type: none"> • Feasibility study of using MDCK cell culture system for influenza vaccine production • The value of MDCK cell culture microcarrier system for countries planning for manufacturing capacity for influenza vaccine <p>Lee Min-Shi, Director, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan (confirmed)</p> <p>17.30 Chairman's closing remarks</p>
--	---